NCT06865352View on ClinicalTrials.gov

Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 13, 2021

Primary Completion Date

January 30, 2025

Study Completion Date

January 30, 2025

Conditions
Acute Lymphoblastic Leukemia ALLAcute Myeloid Leukemia (AML)
Interventions
BIOLOGICAL

HSCT donor leukemia-specific cytotoxic T-cells

donor T-cells stimulated with patient leukemia blasts

Trial Locations (1)

27100

Fondazione IRCCS Policlinico San Matteo, SC Ematologia 2 - Oncoematologia Pediatrica, Pavia

All Listed Sponsors
lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

NCT06865352 - Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter